Enasidenib
- Generic Name
- Enasidenib
- Brand Names
- Idhifa
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17F6N7O
- CAS Number
- 1446502-11-9
- Unique Ingredient Identifier
- 3T1SS4E7AG
- Background
Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML . Patients eligible for this treatment are selected by testing the presence ...
- Indication
Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
- Associated Conditions
- Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT03720366
- Locations
- 🇰🇷
Local Institution - 201, Seoul, Korea, Republic of
🇦🇺Local Institution - 101, Melbourne, Australia
🇰🇷Local Institution - 203, Seoul, Korea, Republic of
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT03515512
- Locations
- 🇺🇸
Johns Hopkins Cancer Center, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT03383575
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Celgene
- Target Recruit Count
- 31
- Registration Number
- NCT03290443
- Locations
- 🇺🇸
New Orleans Center of Clinical Research, Knoxville, Tennessee, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 21
- Registration Number
- NCT02273739
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 345
- Registration Number
- NCT01915498
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.